Healthcare / Medical DevicesNasdaqGM
$15.44
-0.45 (-2.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $6.5M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$619M
P/E
70.2x
↑EV/EBITDA
47.5x
↑ROE
10.4%
↑Gross Margin
75.4%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.3%
FCF CAGR
—
FCF margin
31.2%
FCF / Net income
2.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $52.2M · net income $7.6M · FCF $16.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.2M | $52.2M | $41.0M | $31.8M | $27.2M |
| Net Income | $7.6M | $7.6M | $2.9M | $-4.2M | $-13.3M |
| EBITDA | $11.5M | $11.5M | $6.7M | $-2.6M | $-11.5M |
| EPS | — | — | 0.09 | -0.13 | -0.40 |
| Gross Margin | 75.4% | 75.4% | 74.6% | 73.9% | 73.8% |
| Operating Margin | 8.3% | 8.3% | 3.4% | -15.6% | -46.7% |
| Net Margin | 14.6% | 14.6% | 7.1% | -13.2% | -49.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.09 | 0.01 | 0.01 |
| Current Ratio | 3.34 | 3.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.3M | $16.3M | $6.5M | $-1.1M | $-9.8M |
| Returns | |||||
| ROE | 10.4% | 10.4% | 4.7% | -10.1% | -29.4% |
| Valuation | |||||
| P/E | 70.18 | 70.18 | 54.11 | — | — |
| EV/EBITDA | 47.46 | 47.46 | 13.98 | — | — |
| P/B | 8.26 | 8.26 | 2.54 | 2.90 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | 27.3% | 27.3% | 29.0% | 17.0% | — |
| EPS Growth | — | — | 169.2% | 67.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+202.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.09 → n/d
Residual
+202.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.